Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Flagged first, then by citations

Show all 9 references

Sorted by citations

Items 401–500 of 1,009

Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells
Alinejad, V., Somi, M. H., Baradaran, B., Akbarzadeh, P., Atyabi, F., Kazerooni, H., Kafil, H. S., Maleki, L. A., Mansouri, H. S., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.06.037 · Cited by 85
Therapeutic vaccines for breast cancer: Has the time finally come?
Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.027 · Cited by 84
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83
Breast Cancer in Women Older Than 80 Years
Shachar, S. S., Hurria, A., & Muss, H. B. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.010207 · Cited by 86
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A. M., Cocco, B. D., Pino, M. S., Carlini, P., Cosimo, S. D., Sacchi, I., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj110 · Cited by 81
Notch Signaling and Breast Cancer
Reedijk, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_18 · Cited by 83
The HER2 Signaling Network in Breast Cancer—Like a Spider in its Web
Dittrich, A.-L., Gautrey, H., Browell, D., & Tyson-Capper, A. J. (2014) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-014-9329-5 · Cited by 89
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
Lidgren, M., Jönsson, B., Rehnberg, C., Willking, N., & Bergh, J. C. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm488 · Cited by 80
An RNA Interference Screen Identifies Metabolic Regulators NR1D1 and PBP as Novel Survival Factors for Breast Cancer Cells with the ERBB2 Signature
Kourtidis, A., Jain, R., Carkner, R. D., Eifert, C., Brosnan, M. J., & Conklin, D. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1550 · Cited by 81
The Importance of Biopsy in the Era of Molecular Medicine
Ziv, E., Durack, J. C., & Solomon, S. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000228 · Cited by 80
Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy
Fatima, I., Rahdar, A., Sargazi, S., Barani, M., Hassanisaadi, M., & Thakur, V. K. (2021) · Journal of Functional Biomaterials · doi:10.3390/jfb12040075 · Cited by 80
Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation
Ahmed, S. A., Mendonca, P., Elhag, R. I., & Soliman, K. F. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416091 · Cited by 86
Clinical proteomics: present and future prospects.
Verrills, N. M. (2006) · PubMed · Cited by 80
Chapter 3 The TRAIL to Targeted Therapy of Breast Cancer
Rahman, M., Pumphrey, J. G., & Lipkowitz, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)03003-6 · Cited by 86
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80
Neoplastic stem cells: A novel therapeutic target in clinical oncology
Schulenburg, A., Ulrich-Pur, H., Thurnher, D., Erović, B. M., Florian, S., Sperr, W. R., Kalhs, P., Marian, B., Wrba, F., Zielinski, C. C., et al. (2006) · Cancer · doi:10.1002/cncr.22277 · Cited by 81
Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer
Bullock, K., & Blackwell, K. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0204 · Cited by 80
SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells
Gautrey, H., Jackson, C. R., Dittrich, A.-L., Browell, D., Lennard, T. W. J., & Tyson-Capper, A. J. (2015) · RNA Biology · doi:10.1080/15476286.2015.1076610 · Cited by 85
Efficient Isolation and Accurate In Situ Analysis of Circulating Tumor Cells Using Detachable Beads and a High‐Pore‐Density Filter
Lee, H. J., Oh, J. H., Oh, J. M., Park, J., Lee, J., Kim, M. S., Kim, Y. J., Kang, H. J., Jeong, J., Kim, S. I., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302278 · Cited by 80
Seize the opportunity
Clark, D. P. (2009) · Cancer Cytopathology · doi:10.1002/cncy.20045 · Cited by 80
Anticancer Antibodies
Worland, P. J., Gray, K., Rolfe, P. M., Gray, K., & Ross, M. J. S. (2003) · American Journal of Clinical Pathology · doi:10.1309/y6lpc0lr726l9dx9 · Cited by 80
Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells
Truffi, M., Colombo, M., Sorrentino, L., Pandolfi, L., Mazzucchelli, S., Pappalardo, F., Pacini, C., Allevi, R., Bonizzi, A., Corsi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24968-x · Cited by 79
Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session
Deken, M. M., Kijanka, M. M., Hernández, I. B., Slooter, M. D., de Bruijn, H. S., van Diest, P. J., Henegouwen, P. M. P. V. B. E., Löwik, C. W. G. M., Robinson, D. J., Vahrmeijer, A. L., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.030 · Cited by 79
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs
Weber, W., Czernin, J. G., Phelps, M. E., & Herschman, H. R. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0982 · Cited by 79
Progression and treatment of HER2-positive breast cancer
Davoli, A., Hocevar, B. A., & Brown, T. L. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1208-1 · Cited by 77
Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements
Ulbright, T. M., Hattab, E. M., Zhang, S., Ehrlich, Y., Foster, R. S., Einhorn, L. H., & Liang Cheng, C. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.70 · Cited by 78
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
Harris, C. A., Ward, R. L., Dobbins, T., Drew, A. K., & Pearson, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq593 · Cited by 78
Pertuzumab and trastuzumab: the rationale way to synergy
Richard, S., Selle, F., Lotz, J., Khalil, A., Gligorov, J., & Soares, D. G. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150178 · Cited by 77
Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Bernard-Marty, C., Lebrun, F., Awada, A. H., & Piccart, M. J. (2006) · Drugs · doi:10.2165/00003495-200666120-00004 · Cited by 79
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 79
Combinations of Endocrine and Biological Agents: Present Status of Therapeutic and Presurgical Investigations
Johnston, S. R. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.889s.11.2 · Cited by 77
Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
Brufsky, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318191bfb0 · Cited by 77
Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade
Guo, P., You, J., Yang, J., Jia, D., Moses, M. A., & Auguste, D. T. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4004699 · Cited by 76
Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer CellsIn vitroandIn vivo
Spänkuch, B., Heim, S., Kurunci‐Csacsko, E., Lindenau, C., Yuan, J., Kaufmann, M., & Strebhardt, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0343 · Cited by 76
Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor
Jani, J. P., Finn, R. S., Campbell, M., Coleman, K. G., Connell, R. D., Currier, N. V., Emerson, E. O., Floyd, E., Harriman, S. P., Kath, J. C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3559 · Cited by 76
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
Wong, H., Leung, R. C.-Y., Kwong, A., Chiu, J. W. Y., Liang, R. H.-S., Swanton, C., & Yau, T. C. C. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0165 · Cited by 76
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Zuo, W., Jiang, Y., Wang, Y.-J., Xu, X., Hu, X. Y., Liu, G., Wu, J., Di, G., Yu, K., & Shao, Z.-M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3036 · Cited by 76
De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype
Press, D. J., Miller, M. E., Liederbach, E., Yao, K. A., & Huo, D. (2017) · Clinical & Experimental Metastasis · doi:10.1007/s10585-017-9871-9 · Cited by 74
PPARγ maintains ERBB2-positive breast cancer stem cells
Wang, X., Sun, Y., Wong, J. A., & Conklin, D. S. (2013) · Oncogene · doi:10.1038/onc.2013.217 · Cited by 76
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
Lassus, H. J., Sihto, H. J., Leminen, A., Nordling, S., Joensuu, H., Nupponen, N. N., & Bützow, R. C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602252 · Cited by 75
Mechanisms of Trastuzumab Resistance and Their Clinical Implications
Lan, K., Lu, C., & Yu, D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.026 · Cited by 75
HER2 (erbB-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the «fat features» of the «Mediterranean diet» as an «anti-HER2 cocktail»
Menéndez, J. A., Vázquez‐Martín, A., Ropero, S., Colomer, R., Lupu, R., & Trueta, J. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0137-2 · Cited by 75
Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
Cameron, D., & Stein, S. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1156 · Cited by 75
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
Zsebik, B., Citri, A., Isola, J. J., Yarden, Y., Szöllõsi, J., & Vereb, G. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.018 · Cited by 75
Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
Olejniczak, E. T., Sant, C. V., Anderson, M. G., Wang, G. G., Tahir, S. K., Sauter, G., Lesniewski, R., & Semizarov, D. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0367 · Cited by 75
From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer
Gutschner, T., Richtig, G., Haemmerle, M., & Pichler, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9718-5 · Cited by 78
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Nami, B., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050040 · Cited by 77
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
Wilson, G., Cramer, A., Welman, A., Knox, F., Swindell, R., Kawakatsu, H., Clarke, R. B., Dive, C., & Bundred, N. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603444 · Cited by 74
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Pusztai, L., Anderson, K., & Hess, K. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0809 · Cited by 74
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
Leary, A. F., Hanna, W. M., van de Vijver, M. J., Penault-Llorca, F. M., Rüschoff, J., OSAMURA, R. Y., Bilous, M., & Dowsett, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3989 · Cited by 74
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers
Lamy, P., Fina, F., Mollévi, C., Laberenne, A.-C., Martin, P., Ouafik, L., & Jacot, W. (2011) · Breast Cancer Research · doi:10.1186/bcr2824 · Cited by 74
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour, G., Jadidi-Niaragh, F., Jahromi, A. S., Zandi, K., & Hojjat-Farsangi, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5059-1 · Cited by 67
The Promise and the Hype of ‘Personalised Medicine’
Maughan, T. (2017) · The New Bioethics · doi:10.1080/20502877.2017.1314886 · Cited by 78
Breast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 77
The ErbB2 Signaling Network as a Target for Breast Cancer Therapy
Badache, A., & Gonçalvès, A. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9009-1 · Cited by 78
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
Liu, C., Tseng, L., Su, J.-C., Chang, K.-C., Chu, P., Tai, W., Shiau, C., & Chen, K. (2013) · Breast Cancer Research · doi:10.1186/bcr3457 · Cited by 73
Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
Olsen, K. E., Knudsen, H., Rasmussen, B., Balslev, E., Knoop, A. S., Ejlertsen, B., Nielsen, K. V., Schönau, A., Overgaard, J., & for the Danish Breast Cancer Co-operative Group (2004) · Acta Oncologica · doi:10.1080/02841860310019007 · Cited by 73
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Rexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., & Arteaga, C. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1038 · Cited by 73
Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
Gong, Y., Gilcrease, M. Z., & Sneige, N. (2005) · Modern Pathology · doi:10.1038/modpathol.3800432 · Cited by 73
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
Lago, L. D., Durbecq, V., Desmedt, C., Salgado, R., Verjat, T., Lespagnard, L., Ma, Y., Veys, I., Leo, A. D., Sotiriou, C. P., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0129 · Cited by 73
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
Yu, Y., Yang, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102520 · Cited by 75
A sensitive and high-throughput assay to detect low-abundance proteins in serum
Zhang, H., Cheng, X., Richter, M., & Greene, M. I. (2006) · Nature Medicine · doi:10.1038/nm1378 · Cited by 72
Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors
Zieliński, R., Lyakhov, I. G., Jacobs, A., Chertov, O., Krämer-Marek, G., Francella, N., Stephen, A. G., Fisher, R. J., Blumenthal, R. P., & Capala, J. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad4d5d · Cited by 72
HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial‐to‐mesenchymal transition and metastasis of breast cancer
Gupta, P., & Srivastava, S. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.006 · Cited by 72
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment
Pandey, M. K., Gupta, S. C., Nabavizadeh, A., & Aggarwal, B. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.002 · Cited by 73
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Argiris, A., Wang, C.-X., Whalen, S. G., & DiGiovanna, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1060-02 · Cited by 67
MicroRNAs in cancer drug resistance: Basic evidence and clinical applications
Ghasabi, M., Mansoori, B., Mohammadi, A., Duijf, P. H. G., Shomali, N., Shirafkan, N., Mokhtarzadeh, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26810 · Cited by 71
Targeted therapy in HER2-positive breast cancer
LI, S. G., & Li, L. (2013) · Biomedical Reports · doi:10.3892/br.2013.95 · Cited by 71
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
Rha, S. Y., Moon, Y. H., Jeung, H., Kim, Y. T., Sohn, J., Yang, W. I., Suh, C., Kim, G. E., Roh, J. K., & Chung, H. C. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-2468-4 · Cited by 71
Safety and efficacy of biosimilars in oncology
Schellekens, H., Smolen, J. S., Dicato, M. A., & Rifkin, R. M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30374-6 · Cited by 70
Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship
Bodai, B. I., & Nakata, T. E. (2020) · The Permanente Journal · doi:10.7812/tpp/19.129 · Cited by 73
Antibody–Drug Conjugates for the Treatment of Breast Cancer
Corti, C., Giugliano, F., Nicolò, E., Ascione, L., & Curigliano, G. (2021) · Cancers · doi:10.3390/cancers13122898 · Cited by 69
Triple negative breast cancer: current understanding of biology and treatment options
Kang, S. P., Martel, M., & Harris, L. N. (2008) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3282f40de9 · Cited by 72
Self-citation
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
Kute, T. E., Savage, L., Stehle, J., Kim-Shapiro, J. W., Blanks, M. J., Wood, J. C. S., & Vaughn, J. P. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0700-0 · Cited by 69
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Chu, Q. S.-C., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L. N., Fleming, R. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4417 · Cited by 70
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
Ignatiadis, M., Litière, S., Rothé, F., Riethdorf, S., Proudhon, C., Fehm, T. N., Aalders, K. C., Forstbauer, H., Fasching, P. A., Brain, E. G. C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy211 · Cited by 71
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
Ginestier, C., Adélaı̈de, J., Gonçalvès, A., Repellini, L., Sircoulomb, F., Letessier, A., Finetti, P., Geneix, J., Charafe‐Jauffret, E., Bertucci, F., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210528 · Cited by 69
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression
Aird, K. M., Ding, X., Baras, A., Wei, J.-P., Morse, M. A., Clay, T. D., Lyerly, H. K., & Devi, G. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0370 · Cited by 69
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
Lee, H. J., Kim, J. Y., Park, S. Y., Park, I. A., Song, I. H., Yu, J. H., Ahn, J., & Gong, G. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp51hcgpopwscy · Cited by 69
HER2 expression in cervical cancer as a potential therapeutic target
Chávez-Blanco, A. D., Pérez-Sánchez, V. M., González‐Fierro, A., Vela-Chávez, T., Candelaria, M., Cetina, L., Vidal, S., & Dueñas‐González, A. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-59 · Cited by 69
HER2 breast cancer therapies: a review
Modi, S., & Murphy, C. G. (2009) · Biologics · doi:10.2147/btt.2009.3250 · Cited by 69
Filter‐based isolation, enrichment, and characterization of circulating tumor cells
Khetani, S., Mohammadi, M., & Sanati‐Nezhad, A. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26787 · Cited by 68
Recent advances in novel targeted therapies for HER2-positive breast cancer
Murphy, C. G., & Morris, P. G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352d292 · Cited by 67
A novel interaction between HER2/neu and cyclin E in breast cancer
Mittendorf, E. A., Liu, Y., Tucker, S. L., McKenzie, T., Qiao, N., Akli, S., Biernacka, A., Liu, Y., Meijer, L., Keyomarsi, K., et al. (2010) · Oncogene · doi:10.1038/onc.2010.151 · Cited by 67
Targeting HER2‐positive cancer cells with receptor‐redirected anthrax protective antigen
McCluskey, A. J., Olive, A. J., Starnbach, M. N., & Collier, R. J. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.12.003 · Cited by 66
Safety and feasibility of targeted agent combinations in solid tumours
Park, S. R., Davis, M., Doroshow, J. H., & Kummar, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.245 · Cited by 67
MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer
Matull, W., Andreola, F., Loh, A. X., Adıgüzel, Z., Deheragoda, M. G., Qureshi, U., Batra, S. K., Swallow, D. M., & Pereira, S. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604364 · Cited by 67
Combinatorial Library Strategies for Synthesis of Cationic Lipid-Like Nanoparticles and their Potential Medical Applications
Altınoglu, S., Wang, M., & Xu, Q. (2015) · Nanomedicine · doi:10.2217/nnm.14.192 · Cited by 70
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner
Cardoso, F., Durbecq, V., Laes, J., Badran, B. M., Lagneaux, L., Bex, F., Desmedt, C., Willard-Gallo, K. E., Ross, J. S., Burny, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0104 · Cited by 67
Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines
Kauraniemi, P., Hautaniemi, S., Autio, R., Astola, J. T., Monni, O. M., ELKAHLOUN, A. G., & Kallioniemi, A. H. (2003) · Oncogene · doi:10.1038/sj.onc.1207200 · Cited by 67
MET targeting: time for a rematch
Koch, J. P., Aebersold, D. M., Zimmer, Y., & Medová, M. (2020) · Oncogene · doi:10.1038/s41388-020-1193-8 · Cited by 66
The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease
Lamb, C. A., Saifuddin, A., Powell, N., & Rieder, F. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.09.077 · Cited by 71
Prediction of individual response to anticancer therapy: historical and future perspectives
Unger, F. T., Witte, I., & David, K. A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1772-3 · Cited by 71
Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs
Çiftlik, A. T., Lehr, H., & Gijs, M. A. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211273110 · Cited by 66
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries
Corbo, V., Beghelli, S., Bersani, S., Antonello, D., Talamini, G., Brunelli, M., Capelli, P., Falconi, M., & Scarpa, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr048 · Cited by 67
Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases
Soriano, P., Navarro, S., Gil, M., & Llombart‐Bosch, A. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1041-1 · Cited by 66
HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
Huang, X., Gao, L., Wang, S., Lee, C., Ordentlich, P., & Liu, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2146 · Cited by 66
Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments
Tang, Y., Scollard, D. A., Chen, P., Wang, J., Holloway, C. M. B., & Reilly, R. M. (2005) · Nuclear Medicine Communications · doi:10.1097/00006231-200505000-00006 · Cited by 66

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks